Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash & Current Investments (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Cash & Current Investments for 16 consecutive years, with $916.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 65.79% year-over-year to $916.6 million, compared with a TTM value of $916.6 million through Dec 2025, up 65.79%, and an annual FY2025 reading of $919.4 million, up 35.01% over the prior year.
  • Cash & Current Investments was $916.6 million for Q4 2025 at Arrowhead Pharmaceuticals, roughly flat from $919.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $1.1 billion in Q1 2025 and bottomed at $66.3 million in Q2 2021.
  • Average Cash & Current Investments over 5 years is $467.1 million, with a median of $444.2 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments plummeted 73.49% in 2021, then surged 268.66% in 2023.
  • Year by year, Cash & Current Investments stood at $151.8 million in 2021, then soared by 230.67% to $501.8 million in 2022, then tumbled by 56.1% to $220.3 million in 2023, then skyrocketed by 150.95% to $552.9 million in 2024, then surged by 65.79% to $916.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for ARWR at $916.6 million in Q4 2025, $919.4 million in Q3 2025, and $900.4 million in Q2 2025.